University of Washington
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Washington sits in the top decile of US sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count).
University of Washington: 1,048 sponsored US clinical trials, 156 recruiting.
University of Washington sponsors 1,048 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 720 completed. 104 of these trials are in Phase 3-4 (later-stage) and 320 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 13 trials.
Top-decile sponsor footprint
University of Washington ranks in the top decile of sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
720 of 816 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,048 total, page 1 of 21
An Adapted Evidence-Based Coaching Program for Fathers and Their Young Children in the Context of Home Visiting
NCT07676240
Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing
NCT07667101
Physical Activity Through Health Technology in Axial Spondyloarthritis
NCT07642622
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
NCT07336238
Sodium and Milk Fortification Evaluation of Body Composition Among Very Preterm Infants
NCT07562997
Adapting a Brief Suicide Intervention for Pediatric Primary Care: Enhancing Uptake and Impact
NCT06499740
Nuestro Valor: Increasing Healthier Food Access for Rural Latino Communities Through a Food Retail Intervention
NCT07490652
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
NCT07078604
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
NCT06738368
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
NCT06725173
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT07224100
Copper Supplementation in Cirrhosis
NCT07471542
QT-Digital Mental Health Engagement Study
NCT07278765
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
NCT07302230
Mechanisms of Mindfulness Meditation and Self-Hypnosis for Pain in Older Adults With Chronic Pain
NCT06957743
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
NCT07148947
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
NCT06502691
CIH Stepped Care for Co-occurring Chronic Pain and PTSD
NCT06219408
A Superiority Trial of Radiofrequency Ablation for Low Back Pain
NCT07222462
Comparison of Outcomes of Management of Bowel Obstruction
NCT07084441
Feasibility/Acceptability of a Brief Motivational Intervention for Frequent/High-Intensity Cannabis Use
NCT07011615
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
NCT07097363
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT07112053
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
NCT06948786
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
NCT07225127
CORE (Cognitive Optimization Through Rehabilitation and Education) Study
NCT06859996
The Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA
NCT07221903
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
NCT06710418
Sleep and Performance
NCT07608614
Augmented Momentary Personal Ecological Risk Evaluation
NCT06704958
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
NCT06784726
Integrated Suicide Supports and Safety Planning for Youth
NCT06701006
Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV
NCT07105007
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
NCT07088419
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
NCT06893939
Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT)
NCT06736444
Systematic Redesign of Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
NCT06941428
Effectiveness of Exercise After an ICD
NCT03544489
Motor Recovery Through Plasticity-Inducing Cortical Stimulation
NCT06506279
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
NCT06526299
PAH Exercise Study
NCT06941441
Benefits of Outdoor Walks in Reducing Depressive Symptoms
NCT06989801
Building Research for Intervention Development in Gliosis and Eating Habits
NCT06870578
Impact Trial of Helping Educational Leaders Mobilize Evidence
NCT06586723
Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
NCT06025747
Assessment of Early Pregnancy MAB Completion
NCT06893484
IMAGINE: Pilot Trial of a Digital Group Intervention to Prevent Perinatal Depression
NCT06746337
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
NCT06745076
A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation
NCT06772181
Daily Doxycycline for Early Syphillis
NCT06683638
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 127 |
| Phase 2 | 193 |
| Phase 3 | 39 |
| Phase 4 | 65 |
What is open in the University of Washington pipeline
156 recruiting of 1,048 indexed (15% open); 720 completed (69%).
Phase mix: 104 late (III/IV) vs 320 early (I/II) (early-phase heavy).
Top condition: Depression (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Washington: open-pipeline peers nationwide
Peers matched on 1,048 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,048 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- Bristol-Myers Squibb · 1,025 trials · 7% recruiting
- University of Florida · 1,106 trials · 15% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Arizona State University · 15% recruiting · 187 trials
- Georgetown University · 15% recruiting · 227 trials
Related
What to do with this University of Washington page
1,048 registered trials is a research-attention snapshot, not an endorsement of University of Washington or any single study.
- 156 of University of Washington's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of Washington studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Washington pipeline card: 1,048 registered trials from official public datasets.Report a data error.